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Pulmonary diseaseAbstract Gaucher disease (GD) is themost frequently encountered lysosomal storage disease caused
by inborndefects of themembrane-bound lysosomal enzyme, acidb-glucosidase or glucocerebrosidase.
This defective activity causes an accumulation of glucocerebroside (glucosylceramide) in the
lysosomes of cells derived from the monocyte/macrophage lineage. Glucocerebroside-engorged cells,
termed Gaucher cells, inﬁltrate various organs, leading to multisystemic abnormalities. The
mechanisms by which systemic and organ-speciﬁc involvement is propagated or initiated remain
unclear. Studies are increasingly recognizing the role of immune dysregulation and inﬂammation in
the pathogenesis of Gaucher disease. Many cytokines have been reported as mediators of tissue
damage in Gaucher disease. Bone and lung disease are serious causes of morbidity in non
neuronopathic Gaucher disease. The progress in the understanding of the pathogenesis or relevant
mechanism(s) of Gaucher disease is providing insights into additional therapeutic targets, enabling
the potential for optimized patient outcomes with the use of adjunctive or supplemental agents.
 2015 The Author. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Gaucher disease is an autosomal recessive lysosomal storage
disorder caused by mutations in the gene encoding acid
b-glucosidase (glucocerebrosidase, GCase, EC 3.2.1.45) [1].
Deﬁcient GCase enzymatic activity leads to progressive accu-
mulation of glucocerebroside in the lysosomes of macrophages
in various organs. The large macrophages storing glucocere-
broside, also called ‘Gaucher cells’, are characterized histo-
logically with a small excentrically placed nuclei surrounded
by a bright cytoplasm with striations or crinkles [2,3].
Macrophages are a heterogeneous group of cells, whose
morphology and phenotype differ depending on the tissue/or-
gan and stimuli. They participate in tissue remodeling, host
defense, and many disease processes, and can secrete both anti
or proinﬂammatory cytokines [4].
Although an inﬁnite number of potential phenotypes can be
suggested, macrophages could be associated with two main
types: classical or alternative, depending on the predominant
cytokine in the environment, IFN-c or IL-4/IL-13, respective-
ly. Finally, the stimulus for full activation of classical or alter-
native macrophages is delivered by a TLR or analogous
receptor [5]. Gaucher cells resemble alternative activated
macrophages and are characterized by expression of chi-
totriosidase and CCL18 [6].
The aim of this article is to review the increasingly recog-
nized role of immune dysregulation and inﬂammation in the
pathogenesis of Gaucher disease, with particular emphasis
on bone and lung diseases that are serious causes of disease
morbidity.2. Clinical spectrum and types of Gaucher disease
The symptoms associated with GD are due to the progressive
accumulation of Gaucher cells in various organs. Thus, GD is
a multisystemic disorder with disease manifestation at all ages
dependent on the subtype of GD [1].
Three basic clinical forms of GD can be distinguished
depending on the degree of neurological involvement; howev-
er, recently different forms of GD are considered rather to
reﬂect a continuum ranging from early onset to late onset
disease and from severe forms with neurological symptoms
to mild forms with solely visceral manifestations [7,8].
GD-1 is the most frequent form and accounts for 94% of
all registered GD cases according to the Gaucher Registry
[9]. It leads to a chronic course of disease and the organsfrequently affected are the spleen, liver, bone marrow and bone
and, in severe cases, also the lung and kidney.
Hepatosplenomegaly and hematological complications includ-
ing anemia and thrombocytopenia with bleeding are common
in untreated GD-1 [10]. Acute neuronopathic GD (GD-2)
manifests in early childhood, neurological deterioration pro-
gresses quickly and death generally occurs within the age of
2 years. Subacute neuronopathic GD (GD-3) shows a slower
neurological involvement and usually occurs in adolescence,
although early onset disease has been reported [1,11,12].
3. Pathophysiology of Gaucher disease
The insufﬁcient catabolism of glucosylceramide [GC] and the
engorgement of macrophages by this substrate lead to visceral
manifestations of Gaucher disease, but the mechanisms by
which systemic and organ-speciﬁc involvement are propagated
or initiated remain unclear [8,13].
GC has a ceramide backbone with a b-D-glucopyranoside
bound at the 1-hydroxyl position. GC is the precursor in the
synthesis of 300–400 glycosphingolipids in different mam-
malian cell types. These include ceramide and its degradation
products that regulate cell proliferation, apoptosis, and
modulation of cell signaling pathways [14]. These glycosphin-
golipids also have key roles in diabetes, cancer, kidney, and
other common diseases [3]. Disruption of the balance between
GC synthesis and degradation in Gaucher disease leads to
inﬂammatory conditions and dysfunctions in different tissues
[3,15]. A recent study points to the fundamental role for
GBA (glucosidase, b, acid) gene in immune regulation, and
suggests that GBA mutations in GD may cause widespread
immune dysregulation through substrates accumulation [4].
Two major pathophysiological mechanisms that account
for macrophage activation have been postulated. Sphin-
golipids have been implicated in inﬂammatory and apoptotic
processes, and glucosylceramide might have direct activating
or enhancing effects on macrophage function [16].
An alternative mechanism by which these proinﬂammatory
and anti-inﬂammatory pathways could be activated is through
abnormal folding of mutant proteins in the endoplasmic reti-
culum. Such abnormal folding initiates an unfolded protein
response that can trigger apoptotic or inﬂammatory pathways
in various tissues [17]. It has been suggested that some
mutations in Gaucher disease might lead to proteins that are
abnormally folded or maltrafﬁcked [18], however there is no
direct evidence of unfolded protein response in Gaucher
disease [1,19].
Figure 1 X-ray femur showing markedly reduced bone density, the characteristic Erlenmeyer ﬂask deformity in the distal femur
(abnormal modeling of metaphysis), and evidence of healed fracture neck of the right femur in a child 7 years old with type 1 Gaucher
disease [55].
Figure 2 MRI femur of a 6 year old Gaucher patient type III
showing the characteristic ‘salt and pepper’ appearance, consistent
with homogenous bone marrow inﬁltration [55].
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As indicators of macrophage activation, the levels of interleuk-
in-1b (IL-1b), interleukin-1 receptor antagonist, IL-6, tumor
necrosis factor-a (TNF-a), and soluble IL-2 receptor (sIL-
2R) are elevated in the serum of Gaucher patients, as are
sCD14 and macrophage colony-stimulating factor (MCSF)
[20,21]. These changes could potentially explain some of the
pathological features, since IL-1b, TNF-a, IL-6 and IL-10
may contribute to osteopenia, IL-1b, TNF-a and IL-6 may
contribute to activation of coagulation and hypermetabolism,IL-6 and IL-10 to gammopathies and multiple myeloma
[13,21]. Finally, chitotriosidase, a human chitinase produced
by activated macrophages, is markedly elevated in Gaucher
plasma and is commonly used to examine GD severity and
improvement upon treatment [22].
Other cytokines [3] with increased levels in Gaucher disease
and possibly implicated in pathophysiology of the disease
include IL-8, IL-18, hepatocyte growth factor (HGF), macro-
phage-inﬂammatory protein-1 (MIP-1), pulmonary and activa-
tion–regulated chemokine(CCL18/PARC), transforming
growth factor-beta1 (TGFb1), chemokine ligand 2 (CCL2),
Monocyte chemoattractant protein 1 (MCP1), prostaglandin
E2, COX-2 [15].
Pulmonary and activation-regulated chemokine CCL18/
PARC has been shown to be a highly speciﬁc marker for alter-
natively activated macrophages and is produced by Gaucher
cells [23]. It is constitutively present in human plasma and like-
ly contributes to the physiological homing of lymphocytes and
to the generation of primary immune responses [24]. Serum
concentrations of CCL18/PARC were found to be correlated
reliably with visceral size and hematological parameters,
before and during enzyme replacement therapy [25].
A recent murine study [3] suggested a model in which excess
GC in antigen presenting cells (APCs), i.e., monocytes(M/),
and dentritic cells (DCs), and CD4+ T cells, causes their acti-
vation and positivity for stimulatory and co-stimulatory mole-
cules (CD40, CD80, CD86, MHCII, CD69, CD40L). These
APCs through the CD40 and B7 family molecules and T cells
through the CD40L and CD28 molecules interact and trigger
enhanced responses of the Th1 and Th17 family cytokines.
In addition, with the production of IL17 by the combined
activity of APCs and T cells, initial MU and DC activation
directly triggers a vicious cycle for the release of polymor-
phonuclear (PMN) attracting chemokines, i.e., KC/CXCL1
and MIP2/CXCL2, which causes the PMN migration into
different visceral organs. They concluded that their results
highlight the importance of GC accumulation in APC and
Figure 3 CT chest of a two year old child with type III Gaucher
disease (homozygous L444P) showing bilateral interstitial pul-
monary inﬁltrates, with centrilobular and subpleural nodules,
interlobular and septal thickening, and prominent pulmonary
interstitium [55].
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stimulatory and co-stimulatory molecules as well as enhanced
Th1 and Th17 cytokines [3].
Recently, a study in gaucher mice demonstrated elevated
levels of the proinﬂammatory cytokines, IL-1alpha, IL-1beta,
IL-6, and TNF-alpha, they were detected in the fetal brains
of Gaucher mice. They suggested that accumulated glucocere-
broside or glucosylsphingosine, caused by glucocerebrosidase
deﬁciency, may mediate brain inﬂammation in the Gaucher
mouse via the elevation of proinﬂammatory cytokines [26]. A
recent study of the role of neuroinﬂammation in the patho-
genesis of neuronopathic Gaucher disease showed signiﬁcant
changes in levels of inﬂammatory mediators in the brain of a
neuronopathic Gaucher disease mouse model. They suggested
that once a critical threshold of glucosylceramide storage is
reached in neurons, a signaling cascade is triggered that acti-
vates microglia, which in turn releases inﬂammatory cytokines
that amplify the inﬂammatory response, contributing to
neuronal death [27].
5. Cytokines and the bone in Gaucher disease
Bone involvement is a source of signiﬁcant morbidity among
untreated patients with progressive disease and is highly
refractory to enzyme replacement therapy [7].
5.1. Spectrum of bone morbidity in Gaucher disease
Among patients with GD, the common manifestations of skele-
tal involvement include decreased BMD, Erlenmeyer ﬂask
deformity, bone crises and necrosis, increased fracture risk,
and, in children, growth retardation [28,29], Figs. 1 and 2. All
patients with GD are at risk of bone complications regardless
of age of disease onset, the presence and severity of visceral
or hematological disease or genotype [30]. Enzyme replacement
therapy reduces the episodic frequency of osteonecrosis, and
greatly improves the visceral and hematologic manifestations
but it can neither restore established bone necrosis nor com-
pletely mitigate the risk of infarction crises [6]. The pathological
mechanisms of bone alterations in Gaucher disease are still
poorly understood and seem to be of complex origin [6,11,31].
5.2. Pathogenesis of bone disease
The pathological cascade starts with the progressive accumula-
tion of glucocerebrosides within the bone marrow cavity lead-
ing to a centrifugal expansion of the red bone marrow. The
spine, pelvis and the diaphysial region of the femur and
humerus are initially involved. The displacement of inactive
yellow marrow by red marrow in the periphery alters vascu-
larity and local pressures possibly leading to thrombosis or
infarction by Gaucher cells. Pathologies such as bone crises,
avascular necrosis, bone infarcts and localised cortical thin-
ning may be explained in part by these effects [28,29,32]. In
addition, accumulation of glucocerebrosides seems to induce
macrophage activation which may promote additional inﬂam-
matory processes due to the altered expression of different
macrophage-derived factors and cytokines [33].
The activity of osteoclasts and osteoblasts is inﬂuenced by a
variety of hormones including estrogen, testosterone, parathy-
roid hormone or thyroid hormone. The effects of hormones onthe skeleton can be mediated either directly by hormone
receptors located on osteoblasts and osteoclasts or indirectly
by various other cells of the immune system [11].
Recent work in a murine model of Gaucher disease has
demonstrated abnormalities of osteoblast differentiation indi-
cating that bone formation as well as degradation may be
affected [7,11], as suggested by bone turnover markers in
another study [34].
5.3. Cytokines in the pathogenesis of bone disease
Gaucher disease is associated with release of proinﬂammatory
cytokines such as interleukin (IL)-1, IL-6, tumor necrosis fac-
tor-alpha (TNF-a), that inﬂuence osteoclast and osteoblast
activity. In particular, the changes of some cytokines seem to
be of relevance to the development of osteoporosis in GD:
IL-10 activity may inhibit the osteoblasts activity [35], whereas
IL-1b, IL-6 and M-CSF could enhance bone resorption due to
increased osteoclast activation and formation [36]. Macro-
phage inﬂammatory protein (MIP)-1a and MIP-1b, are elevat-
ed in GD, and may mediate increased bone resorption by
osteoclasts [37].
CXCL8/IL-8 is reported to be increased 2- to 20-fold in the
serum of patients with GD; even after enzyme therapy, being
higher in splenectomized patients compared with those with
intact spleens [36]. CXCL8/IL-8 is found to be highly
expressed in osteoclasts (which originate from macrophage
precursors); it stimulates human osteoclastogenesis and bone
resorption [31].
In a previous study [31], the serum CCL5/RANTES and
monocyte chemoattractant protein 1 (MCP-1) were signiﬁcantly
elevated in GD patients who had osteonecrosis and in the small
group of Gaucher patients who had not met therapeutic goals,
despite enzyme therapy. CCL5/RANTES and MCP-1 attract
and activatemonocytes,macrophages and lymphocytes andhave
been implicated in chronic inﬂammatory disease. A more recent
study [15] described one adult patient with Gaucher disease hav-
ing the mesenchymal stromal cells from bone marrow with
increased expression of CXCL8/IL-8 as well as CCL2/MCP-1.
Studies of CCL18/PARC concentrations in GD found
two-fold greater levels in the serum of GD patients who had
episodes of bone necrosis [31].
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the osteoclast, is highly active in the cleavage of the bone
matrix proteins collagen 1 and osteonectin and its role in bone
resorption, modeling, and turnover is clearly demonstrated
[38]. Cathepsin K was reported to be two- to three folds
increased in sera from GD-patients as compared to healthy
controls, decreasing after ERT. Increased CatK levels may
thus be involved in the development of osteoporosis or lytic
bone lesions in GD [39].
Normally, the activity of osteoclasts and osteoblasts is
regulated by the OPG (osteoprotegerin)/RANK (Receptor
Activator of NF-kB)/RANKL (Receptor Activator of NF-
kB Ligand) system, which plays a central role in bone metabo-
lism. Interestingly, osteoprotegerin (OPG) levels in GD-pa-
tients were comparable to controls [40]. Thus, changes of
bone metabolism seem not to be mediated via the OPG/
RANKL system [33,40].
Changes in total T-lymphocyte numbers and alterations of
CD4+/CD8+ T-lymphocyte ratios may be a further factor, as
an overall decrease of T-lymphocytes with lower CD8+
T-lymphocyte numbers has been reported in GD-patients with
bone involvement [41]. Mucci et al. (2012) [6] reported that
in vitro GCase deﬁciency, and concomitant glucosylceramide
accumulation, generate a state of osteoclastogenesis mediated
in part by pro-resorptive cytokines, especially TNF-a; and, T
cells are involved in osteoclastogenesis in Gaucher disease
chemical model.
This cross-talk of immune cell-osteoclast/osteoblast
interactions, known as ‘osteoimmunology’, reveals bone
metabolism to be a complex network of interacting factors
including bone marrow and immune and bone cells [16]. In
GD, the complex interactions of cells of the bone marrow with
bone, and as two separate compartments closely interacting
with each other, may explain some of the changes seen in bone
disease with GD [6]. However, the development of different
bone pathologies in GD still requires a full explanation, but a
complex, multifactorial pathogenesis as pointed out is likely [7].
A study of mesenchymal stromal cells (MSC) obtained
from GD patients revealed that, although they have a typical
MSC marker phenotype and normal osteocytic and adipocytic
differentiation, there was a marked increase in cyclo-oxyge-
nase-2, prostaglandin E2, interleukin-8 and CCL2 production
compared with normal controls. These changes suggest a
potential role of mesenchymal-derived cells in the genesis of
skeletal disease observed in Gaucher disease patients, in addi-
tion to the primary macrophage transformation related to lipid
storage [15]. Similarly, recent data reported in a chemical mod-
el of GD suggest that, in GD, MSCs represent a stem cell
population that has altered functions and is likely to be
involved in bone pathogenesis [42].
5.4. The impact of therapy on bone manifestations of Gaucher
disease
Therapeutic goals in GD include preventing, stabilizing, and
reversing the progression of skeletal disease [43]. Accumulated
data suggests that earlier treatment initiation decreases skeletal
complications and that bone disease may require a longer
duration of treatment and higher dose than is necessary for
organ involvement and hematopoietic manifestations [1].
When the choices of treatment include multiple enzymepreparations and/or other therapeutic modalities such as small
molecules, the decision of therapy should be tailored indi-
vidually with continuing evaluation [29].
6. Cytokines and the lungs in Gaucher disease
6.1. Spectrum of lung morbidity in Gaucher disease
Lung involvement is not common at presentation of GD and is
correlated with severe forms of the disease [44]. Dyspnea, dif-
fuse and/or patchy lung inﬁltrates, restrictive impairment and
low single breath CO diffusing capacity represent the clinical
disease proﬁle [45]. Respiratory problems result from inﬁltra-
tion of alveolar, interstitial, perivascular, and peribronchial
spaces by lipid-laden macrophages (Gaucher cells) [44].
Patients that are homozygous for 1448G (L444P) mutation
may have an additional risk for lung involvement [46].
A large series of type 1 patients noted pulmonary function
abnormalities in 68%, but only a fraction of them had overt
pulmonary disease [47]. An evaluation of 150 consecutive
patients with type 1 Gaucher disease found that less than
5% have evidence of clinical interstitial lung disease (ILD)
[48]. In contrast, autopsy reports of almost all patients with
type 2 disease reported pulmonary involvement [49].
6.2. Pathogenesis of lung disease
Histopathological features of Gaucher disease are unique in
the lungs. Three patterns of pulmonary pathology have been
noted: (1) interstitial inﬁltration by Gaucher cells with ﬁbrosis,
as in Fig. 3, (2) alveolar consolidation and ﬁlling of alveolar
spaces by Gaucher cells, and (3) capillary plugging by Gaucher
cells and resultant secondary pulmonary hypertension [50,51].
As a complication of chronic liver disease arteriovenous shunt-
ing (hepatopulmonary syndrome) may also be observed [44].
6.3. Cytokines and lung disease
The pulmonary injury in GD may be the result of macrophage
activation by the accumulation of the undigested material due
to lysosomal enzyme dysfunction and surrounding lung
parenchymal damage by proinﬂammatory cytokines secreted,
including IL6, IL10, IL-1b mRNA and TNF-a. These cytoki-
nes are increased in relation to disease severity, suggesting an
etiological link [52].
6.4. The impact of therapy on lung pathology in Gaucher disease
Enzyme replacement has been shown to be effective for reduc-
tion of organomegaly and improvement of hematological
parameters, however, pulmonary manifestations display a
comparably slower and more heterogeneous response to
enzyme treatment [53,54].
7. Conclusions
Although bone disease is common in GD while symptomatic
pulmonary involvement is uncommon, both represent a seri-
ous morbidity in Gaucher disease, markedly impairing the
patient’s quality of life. Cytokines are highly involved in the
212 A.A.G. Tantawypathogenesis of both conditions. The response to enzyme
replacement therapy is slow and variable in both bone and pul-
monary involvement, so, newer therapeutic options should be
offered to these patients. Recognition of the role of cytokines
in the pathogenesis of GD bone and lung involvement, suggest
the possibility of the future role of adjuvant anti-cytokine ther-
apy to control the disease associated immuno-inﬂammatory
pathology.
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